Filing Flows

Filing Flows › 8-K events › Guardant Health

Guardant Health: departure or appointment of directors and officers

Form 8-K filed Nov 3, 2026 · items 5.02

What the filing says

On November 2, 2026, the independent members of the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) approved the grant of performance-based restricted stock units (“PSU Awards”) under the Company’s 2018 Incentive Award Plan (the “Plan”) to each of the Company’s founders and Co-Chief Executive

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Guardant Health at a glance

Latest quarterQ3 2026
Revenue$361.0M
Revenue Y/Y+36%
Operating margin-36.8%
IndustryServices-Medical Laboratories

Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%. The chart follows the revenue to costs, profit and cash.

Guardant Health: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.